Scottish Medicines Consortium clostridium botulinum type A (Dysport)

Scottish Medicines Consortium clostridium botulinum type A (Dysport)

in the absence of a submission from the holder of the marketing authorisation:

clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is not recommended for use within NHS Scotland.

Indication under review: Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Name: clostridium botulinum type A (Dysport)
SMC Drug ID: 1321/18
Manufacturer: Ipsen Ltd
Indication: Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 March 2018

To read more Press Release articles, click here.